Verospilactone capsules 100mg, 30pcs

Composition

1 tablet contains:

Active ingredient:

spironolactone 100 mg

Pharmacological action

Spironolactone, being an aldosterone antagonist, competitively binds to aldosterone receptors in the distal renal tubules.

Aldosterone acts as a potassium-sparing diuretic by increasing the amount of sodium and water removed from the body while delaying the release of potassium and magnesium.

The diuretic effect usually develops on the 2nd-5th day of treatment and persists for 2-3 days after discontinuation of the drug.

Indications

• Edematous syndrome in chronic heart failure, cirrhosis of the liver (especially in the simultaneous presence of hypokalemia and hyperaldosteronism), nephrotic syndrome; 
• essential hypertension in adults;
• ascites;
• diagnosis and treatment of primary hyperaldosteronism (Conn’s syndrome);
• prevention of hypokalemia in the treatment with saluretics and in patients receiving cardiac glycosides, myasthenia gravis (auxiliary agent).

Contraindications

Hypersensitivity, Addison’s disease, acute or rapidly progressive renal failure, chronic renal failure with a significant decrease in excretory function (creatinine clearance less than 10 ml/min), anuria, hyperkalemia, hyponatremia, hypercalcemia.

With caution:  Decreased excretory function of the kidneys, impaired liver function (increased sensitivity to changes in electrolyte balance), diabetes mellitus (especially diabetic nephropathy), predisposition to metabolic acidosis (with acidosis, the hyperkalemic effect of spironolactone increases, spironolactone can contribute to the development of acidosis), menstrual disorders and/or breast enlargement, AV block (possibly increased due to the development of hyperkalemia).

Side effects

Nervous system and sensory disorders: dizziness, drowsiness, lethargy, lethargy, headache, ataxia, confusion.

From the digestive tract: nausea, vomiting, diarrhea, cramps, intestinal colic, gastritis, ulceration and bleeding in the gastrointestinal tract, impaired liver function.

From the genitourinary system: gynecomastia (usually reversible, in rare cases it can persist after drug withdrawal), breast pain, erectile dysfunction in men, decreased potency in men, menstrual disorders or amenorrhea, metrorrhagia in the menopausal period, hirsutism, voice changes in women.

From the side of the skin: maculopapular or erythematous skin rashes, alopecia, hypertrichosis, pruritus, urticaria.

Other services: calf muscle spasms, benign breast neoplasms, chest pain, leukopenia (including agranulocytosis), thrombocytopenia, electrolyte imbalance, hyperkalemia, increased blood urea nitrogen, creatinine, osteomalacia, drug fever.

Interaction

Pharmacodynamic interaction

Verospilactone reduces the sensitivity of blood vessels to norepinephrine. This should be taken into account when performing general and local anesthesia in patients taking Verospilactone.

Concomitant use of potassium-sparing diuretics with Indometacin or ACE inhibitors leads to the development of hyperkalemia. In combination with other diuretics and antihypertensive drugs, Verospilactone enhances their effect. Therefore, when adding Verospilactone to the treatment regimen, the dosage of such drugs should be reduced.

Pharmacokinetic interaction

Spironolactone has been shown to increase digoxin T 1/2. This can lead to an increase in the concentration of digoxin in the blood up to toxic, so when they are taken together, it is necessary to reduce the dose or increase the interval between digoxin doses.

Acetylsalicylic acid weakens the diuretic effect of spironolactone by blocking the secretion of the main metabolite – canrenone in the renal tubules. Indometacin and mefanamic acid have been shown to inhibit the excretion of canrenone.

Spironolactone increases the metabolism of antipyrine.

How to take, course of use and dosage

Tablets are taken orally after a meal.

Adults can take the daily dose in one or more doses.

Edema on the background of chronic heart failure:  the initial dose is 25 mg/day, the maximum dose is 100 mg/day. The maintenance dose is determined individually.

Edema on the background of cirrhosis of the liver:  100-400 mg / day (depending on the ratio of potassium and sodium). The maintenance dose is determined individually.

Peripheral edema on the background of nephrotic syndrome:  the daily dose is 100-200 mg/day.

Essential hypertension in adults: 50-100 mg / day. If necessary, the daily dose can be gradually increased to 200 mg/day over two weeks. Duration of treatment – at least 2 weeks.

Children: usually prescribed at the rate of 3 mg / kg of body weight per day. The dose should be selected based on their response and tolerability of the drug. The frequency of use is usually 1-2 times a day.

Diagnosis and treatment of primary hyperaldosteronism:  it can be used for initial diagnosis, as an indirect indicator of primary hyperaldosteronism in patients on a normal diet. Long test: adults – 400 mg / day for 3-4 weeks. Elimination of hypokalemia and arterial hypertension indirectly supports the diagnosis of primary hyperaldosteronism. Short test: the daily dose for adults is 400 mg for 4 days.

If during the period of taking spironolactone, the concentration of potassium ions in the blood serum increases, but decreases when spironolactone is discontinued, primary hyperaldosteronism should be considered as a possible diagnosis. After the diagnosis of hyperaldosteronism is made using more informative diagnostic tests, spironolactone can be taken in preparation for surgery at a dose of 100 to 400 mg / day.

In patients who are not subject to surgery, Verospilactone can be used as long-term maintenance therapy in the lowest effective doses, which are set for the patient individually.

Prevention of hypokalemia in the treatment with saluretics:  25-100 mg / day.

Missed dose: take the missed dose as soon as possible. Do not take it if there is no time left before taking the next dose. Do not take a double dose.

Overdose

Symptoms:  nausea, vomiting, drowsiness, confusion, skin rash, diarrhea. There may be a violation of the electrolyte balance and dehydration of the body.

Treatment:  Verospilactone should be stopped immediately, induce vomiting, and flush the stomach.

There is no specific antidote. Symptomatic treatment of dehydration, electrolyte imbalance, and hypotension should be performed.

Elimination of hyperkalemia is achieved by rapid use of glucose (20-50% solutions) and insulin at the rate of 0.25-0.5 units of insulin per 1 g of glucose.

Potassium-releasing diuretics and ion-exchange resins are used.

Form of production

Tablets

Shelf life

2 years

Active ingredient

Spironolactone

Conditions of release from pharmacies

By prescription

Dosage form

Capsules

Description

For adults as directed by your doctor

Indications

Heart Failure, Hypertension, Cirrhosis of the liver